For more than 10 years, the Clermont-Ferrand University Hospital has led the CML Observatory, a national real-world data registry dedicated to chronic myeloid leukaemia (CML). This major project, overseen by Professor Marc Berger, brings together the biological haematology department, the cell therapy and adult clinical haematology unit, and the biometrics division of the Clinical Research and Innovation Directorate.
The Observatory centralises clinico-biological data from over 2,000 patients enrolled across more than 21 hospital centres.
It is part of a nationwide collaborative initiative involving physicians, biologists, researchers, clinical research associates, data managers, and biostatisticians. Data are collected with informed consent, hosted in a secure environment, and currently transitioning to a certified CNIL-compliant health data warehouse (EDS).
Although this disease is still considered relatively rare (25 patients per year in Auvergne), observing it on a national scale makes it possible to acquire new knowledge to refine patient care and improve long-term treatment.
Several publications have already been produced, highlighting the strength of this Observatory—unique in France and remarkable worldwide—as a real-world research tool. Two additional scientific publications are planned for 2026.
